Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Multidrug resistant bacteria in a neurological rehabilitation hospital
Journal Information
Vol. 40. Issue 7.
Pages 405-407 (August - September 2022)
Vol. 40. Issue 7.
Pages 405-407 (August - September 2022)
Letter to the Editor
Full text access
Multidrug resistant bacteria in a neurological rehabilitation hospital
Microorganismos multirresistentes en un hospital monográfico de rehabilitación neurológica
Visits
153
Margarita Vallèsa,
Corresponding author
mvalles@guttmann.com

Corresponding author.
, Conxita Romeroa, Laura Cerveraa,b, Sergiu Albua
a Institut Guttmann, Badalona, Barcelona, Spain
b Hospital Universitari Dr Peset, Valencia, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

The Institut Guttmann (IG) is a centre dedicated to neurological rehabilitation, where patients affected by spinal cord injury (SCI), brain damage and other neurological diseases are treated. As in all health centres, the control of multidrug-resistant organisms (MDROs) is a challenge, increased by the peculiarities of this type of centre (admissions from other hospitals, therapeutic activities in common spaces, personal contact due to patients' dependence, limitation of rehabilitation treatment). The IG has an MDRO control programme that includes screening on admission, isolation of affected patients, hand hygiene and an optimisation programme for the use of antibiotics.1

In order to describe the MDROs presented by patients on admission to the IG, as well as the MDRO infections they suffer during their stay and related factors, we carried out a prospective longitudinal cohort study of the 502 patients admitted for rehabilitation treatment during 2019.

Demographic data (age and sex) was collected, along with details of the cause and date of acquisition of the neurological injury, functional level at admission (functional independence measure2) and length of stay in the IG. Regarding MDROs, we compiled the results of the screening performed on admission (<48 h from the date of admission), which included nasal smears, rectal smears, urine cultures, cultures of skin wounds, and cultures of tracheal aspirates in the case of tracheostomy. Cultures were performed in the microbiology laboratory following the recommendations of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [Spanish Society of Infectious Diseases and Clinical Microbiology].3 Throughout hospitalisation, infections caused by MDROs occurring 48 hours after admission were recorded, including details of their aetiology and site. The diagnosis of infection was made based on the presence of suggestive symptoms together with radiological criteria (respiratory infection), laboratory tests and positive culture, taking into account the characteristics of the patients (neurogenic bladder, permanent or intermittent bladder catheterisation, tracheostomy).

The statistical analysis performed and the results are summarised in Table 1 and highlight that MDROs were detected in 31% of the patients on admission and 6.6% suffered some MDRO infection during their stay in the IG.

Table 1.

Multidrug-resistant organisms detected on admission and causing infection during hospitalisation in relation to the characteristics of the patients studied.

  Total percentage of patients  Percentage Neurological injury groupGender (male/female)  Age (years; mean and range)  Duration of injury (days; mean and range)  Functional level at admission (total FIM; mean and range)  Length of hospital stay (days; mean and range) 
  Total (n = 502)  BD (n = 341)  SCI (n = 127)  OTHER (n = 34)           
Sample characteristics  68%  25%  7%  67% / 33%  48.7 (8-88)  173 (8-17,175)  65 (18-126)  70 (1-308) 
MDRO screening at admission
Patients with 1 or >1 MDRO at admission  31%  33%a  32%a  12%  68% / 32%  46.6 (4-83)  183 (8-5,386)  55 (18-125)b  82 (4-308) 
Patients with no MDRO at admission  69%  67%  68%  88%  66% / 34%  46.8 (0-88)  168 (9-17,175)  69 (18-126)  64 (1-308) 
Isolated MDROs on admission
ESBL Klebsiella pneumoniae,  14%  13%  20%c  6%  70% / 30%  47 (7-85)  121 (1-940)  58 (18-119)  91 (22-308) 
ESBL Escherichia coli  8%  8.5%  9.4%  2.9%  63% / 37%  49 (13-75)  364 (10-5,386)  59 (18-125)  70 (6-170) 
Methicillin-resistant Staphylococcus aureus  6%  7.3%  2.3%  2.9%  79% / 21%  45 (4-74)  114 (30-473)  49 (18-125)  77 (4-173) 
Multiresistant Pseudomonas aeruginosa  4%  3.8%  3.1%  2.9%  67% / 33%  50 (13-72)  103 (29-201)  43 (18-115)  99 (10-236) 
Carbapenemase-producing Enterobacteriaceae  1.3%  1.4%  1.5%  57% / 43%  37 (14-58)  82 (8-110)  51 (18-113)  87 (43-174) 
Multiresistant Acinetobacter baumanii  1.1%  1.4%  0.7%  83% / 17%  28.1 (14-50)  181 (68-321)  42.2 (18-101)  112 (43-181) 
Other multidrug-resistant organisms  1.7%  2.6%  67% / 33%  39.8 (16-60)  128.6 (28-532)  35.9 (18-83)  61 (28-128) 
MDRO infections on admission
Patients with 1 or >1 MDRO infection  6.6%  4.6%  12.5%d  2.9%  73% / 27%  51.3 (9-78)  98.3 (8-489)  47.7 (18-103)  112.5 (36-236)e 
Patients with no MDRO infection  93.4%  95.4%  87.5%  97.1%  66% / 44%  46.4 (0-88)  229.7 (1-20,870)  66 (18-126)  67 (1-308) 
MDROs causing infections
ESBL Klebsiella pneumoniae,  2%  0.5%  7%  2.9%  83% / 17%  58 (10-78)  44 (8-110)  60 (39-98)  126 (38-236) 
ESBL Escherichia coli  2%  1.7%  3.9%  73% / 27%  45 (9-74)  102 (10-489)  46 (18-103)  107 (36-177) 
Methicillin-resistant Staphylococcus aureus  1.5%  1.7%  1.5%  75% / 25%  52 (33-74)  125 (54-281)  32 (18-55)  137 (59-236) 
Multiresistant Pseudomonas aeruginosa  1%  1.1%  0.7%  60% / 40%  47 (33-60)  138 (91-236)  26 (18-47)  170 (41-346) 
Carbapenemase-producing Enterobacteriaceae 
Multiresistant Acinetobacter baumanii 
Other multidrug-resistant organisms  0.6%  0.2%  1.5%  100% / 0%  46 (28-74)  152 (58-321)  55 (20-101)  111 (55-177) 
Infection site
Urological  5.3%  2.3%  11.8%  2.9% 
Respiratory  2.3%  2%  0.7% 
Cutaneous  1.1%  0.5%  1.5% 
Other  0.1%  0.7% 

ESBL: extended spectrum beta-lactamase; BD: brain damage; FIM: functional independence measure; SCI: spinal cord injury; MDRO: multidrug-resistant organism.

a

p = 0.04. Chi-square test shows a higher probability of presenting MDROs on admission in patients with brain damage or spinal cord injury than in other neurological diseases.

b

p < 0.001. Student's t-test shows a worse functional level at admission (lower FIM) in patients with MDROs on admission compared to patients without MDROs on admission.

c

p = 0.04. Chi-square test shows a higher probability of detecting ESBL Klebsiella pneumoniaeon on admission in patients with spinal cord injury than in patients with brain damage or other neurological diseases.

d

p = 0.006 Chi-square test, shows a higher probability of MDRO infections in patients with spinal cord injury than in patients with brain damage or other neurological diseases.

e

p < 0.001 Student's t-test, shows a longer hospital stay at the Institut Guttmann in patients with MDRO infections during hospitalisation compared to patients without MDRO infection.

The most frequent MDROs isolated on admission were extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA), as has been described in the few similar studies published, but we differed in finding multiresistant Pseudomonas aeruginosa (P. aeruginosa), but not vancomycin-resistant Enterococcus spp. This variability is due to methodological differences and/or differences in the prevalence of MDROs, depending on the geographical area.4–6 MDRO infections in neurorehabilitation centres have hardly been described in the literature. Our results coincide, in terms of the most common site (urological) and aetiology (ESBL Enterobacteriaceae, MRSA), with the Estudio de Prevalencia de Infecciones Nosocomiales en España [Prevalence Study of Nosocomial Infections in Spain] for the rehabilitation specialty.7 We highlight the presence of infections by multiresistant P. aeruginosa and not by carbapenemase-producing Enterobacteriaceae or multiresistant Acinetobacter baumanii. Except for ESBL Klebsiella pneumoniae, which is more frequent on admission in patients with SCI, we have not found other patient characteristics related to a certain MDRO detected on admission or as an aetiology of infection.

As for factors related to the presence of MDROs, we agree with other studies that low functional level is a risk factor for presenting MDROs at admission, unlike the length of time with the injury or other factors described in the literature (age, sex).4–6 MDRO infections are more frequent in patients with SCI, due to a higher incidence of urological infections,8 and patients with MDROs at admission (61% with MDROs vs. 39% without MDROs at admission; p < 0.001 chi-square test). Although 6.6% of patients had MDRO infections during hospitalisation, it is noteworthy that in 39% of them MDROs were not detected on admission, which reveals the transmission and/or acquisition of new MDROs during the hospital stay, a circumstance already described in our centre for ESBL Enterobacteriaceae.9

In patients with MDRO infection, the length of hospital stay in the IG was significantly longer, in the same way as has been described in nosocomial infections in general.10

In conclusion, the notable presence of patients with MDROs on admission, especially in those most dependent, and its possible consequences (transmission, infection, hospital stay), make control measures in neurorehabilitation centres essential, especially screening on admission.

Acknowledgements

To Hatice Kumru, Ana Alonso, Mariona Secanell and Eloy Opisso for their invaluable contribution to the completion of this study.

References
[1]
Red Nacional de Vigilancia Epidemiológica (RENAVE).
Protocolo de vigilancia y control de microorganismos multirresistentes o de especial relevancia clínico-epidemiológica (Protocolo-MMR).
(2016),
[2]
S. Mackintosh.
Functional independence measure.
Aust J Physiother, 55 (2009), pp. 65
[3]
J. Oteo, G. Bou, F. Chaves, A. Oliver.
Microbiological methods for surveillance of carrier status of multiresistant bacteria.
Enferm Infecc Microbiol Clin, 35 (2017), pp. 667-675
[4]
E. Bilavsky, Y. Lerman, A. Rabinovich, J. Salomon, C. Lawrence, A. Rossini, et al.
Carriage of methicillin-resistant Staphylococcus aureus on admission to European rehabilitation centres--a prospective study.
Clin Microbiol Infect, 18 (2012), pp. E164-E169
[5]
E. Bilavsky, E. Temkin, Y. Lerman, A. Rabinovich, J. Salomon, C. Lawrence, et al.
Risk factors for colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae on admission to rehabilitation centres.
Clin Microbiol Infect, 20 (2014), pp. O804-O810
[6]
J.D. Rollnik, M. Bertram, C. Bucka, M. Hartwich, M. Jöbges, G. Ketter, et al.
Outcome of neurological early rehabilitation patients carrying multi-drug resistant bacteria: results from a German multi-center study.
[7]
Sociedad Española de medicina Preventiva Salud Pública e Higiene.
EPINE. estudio de Prevalencia de Infecciones Nosocomiales en España n.° 30.
[8]
L.Y. Garcia-Arguello, J.C. O’Horo, A. Farrell, R. Blakney, M.R. Sohail, C.T. Evans, et al.
Infections in the spinal cord-injured population: a systematic review.
Spinal Cord, 55 (2017), pp. 526-534
[9]
A. Adler, A. Baraniak, R. Izdebski, J. Fiett, A. Salvia, J.V. Samso, et al.
A multinational study of colonization with extended spectrum β-lactamase-producing Enterobacteriaceae in healthcare personnel and family members of carrier patients hospitalized in rehabilitation centres.
Clin Microbiol Infect, 20 (2014), pp. O516-O523
[10]
J.M. Mylotte, R. Graham, L. Kahler, B.L. Young, S. Goodnough.
Impact of nosocomial infection on length of stay and functional improvement among patients admitted to an acute rehabilitation unit.
Infect Control Hosp Epidemiol, 22 (2001), pp. 83-87

Please cite this article as: Vallès M, Romero C, Cervera L, Albu S. Microorganismos multirresistentes en un hospital monográfico de rehabilitación neurológica. Enferm Infecc Microbiol Clin. 2022;40:405–407.

Copyright © 2021. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos